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Background: Panax notoginseng has been used as a general tonic agent to invigorate human body for
millennia in China and continued to be used until present.
Methods: Some chromatographic methods were performed to isolate pure triterpenoids, and their
structures were determined by nuclear magnetic resonance (NMR) experiments. Anti-diabetes activities
of isolated compounds were evaluated through their inhibitory activity of protein tyrosine phosphatase
1B (PTP1B) enzyme.
Results and Conclusion: Three new dammarane-type triterpenoids, notoginsenoside-LX (1), notoginse-
noside-LY (2), and notoginsenoside-FZ (3) together with eighteen known compounds were isolated from
the Panax notoginseng leaves. The structure-activity relationship of the compounds with dammarane-
type triterpenoids and their PTP1B inhibitory activity were also reported. Results showed that com-
pounds 2, 15, 20, and 21 can signiﬁcantly inhibit the enzyme activity of PTP1B in a dose-dependent
manner, with inhibitory concentration 50 (IC50) values of 29.08 mM, 21.27 mM, 28.12 mM, and 26.59 mM,
respectively. The results suggested that Panax notoginseng leaves might have potential as a new thera-
peutic agent for the treatment of diabetes.
opyright  2013, The Korean Society of Ginseng, Published by Elsevier.Open access under CC BY-NC-ND license. 1. Introduction
Panax notoginseng (Chinese ginseng) or “sanqi” is a functional
food in China [1]. Based on the United States (US) Dietary Supple-
ment Health and Education Act (DSHEA) of 1994, notoginseng tea
or capsules are being sold as over-the-counter dietary supplements
in the US health food market [2]. P. notoginseng has been used for
many years because of its beneﬁcial anti-inﬂammatory and blood
circulation properties [3,4]. P. notoginseng also possesses several
interesting pharmacological activities, such as anti-aging, anti-
tumor, immunostimulating, and radioresistance activities [5e8].
P. notoginseng belongs to the same genus as Korean ginseng (Panax
ginseng Meyer) and American ginseng (Panax quinquefolius L.), and
their main components are similar.
Dammarane triterpene saponins are the major bioactive in-
gredients of P. notoginseng. To date, more than 60 dammarane-type
triterpenoids have been obtained from P. notoginseng [9]. The mainse Medicine, Shenyang Pharmaceut
inseng, Published by Elsevier.Openconstituents of these dammarane-type triterpenoids are ginseno-
sides that contain an aglycone with a dammarane skeleton. In
continuing the search for the minor bioactive constituents from
P. notoginseng, the leaves of this plant were chemically investigated.
Protein tyrosine phosphatase 1B (PTP1B) is a major non-
transmembrane phosphotyrosine phosphatase in classical insulin-
targeted tissues. PTP1B overexpression can inhibit the increased
expression of insulin in insulin-resistant states [10]. A previous
report suggested that PTP1B can be used to treat obesity and type-2
diabetes mellitus [11].
In the present study, 21 dammarane-type triterpenes (3 new
and 18 known ones) were isolated from the leaves of P. notoginseng.
Besides the isolation and structure elucidation of the new com-
pounds, the inhibitory effects of all compounds on PTP1B activity
were evaluated. The current data suggest that some compounds
can be developed as antidiabetic agents in future translational
studies.ical University, 51#, 103 Wenhua Road, Shenyang 110016, People’s Republic of China.
 access under CC BY-NC-ND license. 
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2.1. General experimental procedure
Column chromatography (cc): silica gel (SiO2: 300e400 mesh,
Qingdao Marine Chemical Group Co., Qingdao, China); macro-
porous resin D 101 (Tianjin Chemical Co., Tianjin, China); RP C18
silica gel (300e400 mesh, Agela Technologies Co., Tianjin, China);
Sephadex LH-20 (Pharmacia Co., Peapack, USA). Optical rotations
were measured on a Perkin-Elmer 241MC polarimeter (Perkin-
Elmer Co., Waltham, USA) using methanol (Concord Technology
Co., Tianjin, China) as the solvent. Nuclear magnetic resonance
(NMR) spectra were recorded with a Bruker ARX-600 (Bruker Co.,
Karlsruhe, Germany) (1H, 600 MHz; 13C, 150 MHz) spectrometer in
C5D5N with tetramethylsilane as internal standard. Infrared (IR)
spectra on a Bruker Inter-Frame Space (IFS)-55 infrared spectro-
photometer (Bruker Co., Karlsruhe, Germany) were recorded in
Potassium bromide (KBr) disks. High-resolution electrospray ioni-
zation mass spectra (HRESIMS) were recorded on an Agilent 1100
LC-MSD (Mass Spectrometer Detector) TOF (time-of-ﬂight) system
(Agilent Technologies, Inc., Santa Clara, USA) [ionization mode,
positive; nebulizing gas (N2) pressure, 35 psi; drying gas (N2) ﬂow,
12 L/min; temp, 325C; capillary voltage, 3,000 V; fragmentor
voltage, 225 V]. Gas chromatography (GC) was performed on the
Agilent technologies 6890N apparatus (Agilent Technologies, Inc.,
Santa Clara, USA) with an OV-17 column (30 m  0.32 mm). The
column temperature was programmed from 80C to 280C at a rate
of 10C/min. Nitrogenwas used as the carrier gas at 1.5mL/min. The
injector and detector temperature was at 280C and the injection
volume was 1 mL with the split ratio being 10:1. All chemicals and
solvents were analytical or high performance liquid chromatog-
raphy (HPLC) grade and purchased from Lab Co. Ltd. (Lab Science
and Trade Co., Ltd, Shenyang, China). Reversed-phase preparative
HPLC was carried out on an octadecyl silica column [YMC-Pack
Octadecylsilyl (ODS) A (YMC Co., Kyoto, Japan) (250 mm  10 mm,
5 mm)] at 25C at a ﬂow rate of 3.0 mL/min with the eluent MeOH/
H2O 66:34 (HPLC system I), 70:30 (HPLC system II), 75:25 (HPLC
system III), 80:20 (HPLC system IV), 82:18 (HPLC system V), or 9:1
(HPLC system VI). Ultraviolet (UV) spectrophotometric detection
was carried out at 203 nm.
2.2. Plant material
P. notoginseng leaves were from the Yunnan province of the
People’s Republic of China and identiﬁed by Professor Jincai Lu of
Shenyang Pharmaceutical University.
2.3. Extraction and isolation
Air-dried P. notoginseng leaves (35 kg) were extracted with 70%
ethanol (2  350 L) and then evaporated under vacuum at 30C.
Ethanol extracts (1.6 kg) were applied on a macroporous resin
column (10.5 kg) preconditioned with distilled water. Elution
began with water to remove impurities and then with 70% ethanol
(100 L) to isolate the saponin fraction, which was dried with a spray
dryer to yield the total saponins (1 kg).
The total saponin (1 kg) was fractionated by silica gel column
(300 mm  1,600 mm, 30 kg) using a gradient of CH2Cl2/CH3OH
(7:1 350 L4:1 350 L3:1 350 L) and CH3OH (300 L) to obtain 10
fractions, AJ. Fraction A (18 g) was subjected to chromatography
on silica gel (70mm 800mm, 400 g) and then elutedwith ligarine
and acetone in increasing polarity to yield 10 fractions, A1A10,
compounds 15 (20 mg), 16 (10 mg), and 17 (20 mg). Fractions B
(20 g), C (25 g), D (23 g), and E (13 g) were subjected to chroma-
tography on silica gel (70 mm  800 mm, 500 g) and then elutedwith methanol and dichloromethane in increasing polarity to yield
seven fractions, B1B7, eight fractions, C1C8, 10 fractions,
D1D10, and ﬁve fractions, E1E5. Fraction C4 (100 mg) was
passed over a Sephadex LH-20 column (30 mm  800 mm, 80 g)
and then eluted with MeOH (500 mL) to obtain compound
20 (15 mg). Fraction E3 (1 g) was subjected to chromatography
on ODS (30 mm  150 mm, 50 g) and then eluted successively
with solvents of decreasing polarity (MeOH/H2O, 4:6 600 mL
6:4 600 mL7:3 600 mL9:1 600 mL1:0 600 mL) to yield seven
fractions, E3-1E3-7. Compound 21 (8 mg) was obtained as gran-
ulated crystal from E3-6. Fractions F (18 g), G (15 g), H (20 g), and I
(20 g) were subjected to chromatography on ODS (50 mm 
250 mm, 250 g) and then eluted successively with solvents of
decreasing polarity (MeOH/H2O, 3:7 3 L5:5 3 L7:3 3 L9:1 3
L1:0 3 L) to yield 11 fractions, F1F11, eight fractions, G1G8,
seven fractions, H1H7, and eight fractions, I1I8. Compound 1
(10mg)was obtained as granulated crystal from F-5. Isolation of the
following 15 compounds was performed by preparative HPLC:
compounds 2 (18 mg; tR 75.0 min), 12 (30 mg; tR 38.9 min), 13
(20mg; tR 46.8min), and 14 (60mg; tR 53.5min) were isolated from
fraction D3 (500 mg) by HPLC system I; compound 18 (4 mg; tR
41.8 min) was isolated from fraction A2 (60 mg) by HPLC system VI;
compounds 3 (15mg; tR 70.3 min), 4 (15mg; tR 45.8 min), 5 (14 mg;
tR 58.9 min), and 6 (14 mg; tR 65.9 min) were isolated from fraction
I4 (200 mg) by HPLC system II; compounds 7 (40 mg; tR 33.5 min)
and 8 (60 mg; tR 49.6 min) were isolated from fraction H5 (500 mg)
by HPLC system III; compounds 9 (8 mg; tR 17.5 min), 10 (70 mg; tR
26.5 min), and 11 (65 mg; tR 33.7 min) were isolated from fraction
G6 (1 g) by HPLC system IV; compound 19 (6 mg; tR 122.9 min) was
isolated from fraction B2 (40 mg) by HPLC system V.
2.4. Notoginsenoside-LX (1)
(20S,23R)-3b-hydroxy-12b,23-epoxy-dammar-24-ene 3-O-b-D-
glucopyranoside-20-O-a-L-arabinofuranosyl-(1/6)-b-D-gluco-
pyranoside (notoginsenoside-LX): white amorphous powder; [a]
20 D ¼ 20.8 (c ¼ 0.30, MeOH); IR nmax 3425, 2930, 1637, 1452,
1384, 1079, 620 cm1; Libermann-Burchard and Molish reactions
were positive; 1H and 13C NMR: see Table 1; HRESIMSm/z 937.5097
[MþNa]þ (calculated for C47H78O17Na, 937.5137).
2.5. Notoginsenoside-LY (2)
(20S,23R)-3b-hydroxy-12b,23-epoxy-dammar-24-ene 20-O-a-
L-arabinofuranosyl -(1/6)-b-D-glucopyranoside (notoginseno-
side-LY): white granulated crystal; [a]20 D ¼ 11.4 (c ¼ 0.45,
MeOH); IR nmax 3419, 2942, 1637, 1452, 1384, 1043, 621 cm1; Lib-
ermann-Burchard and Molish reactions were positive; 1H and 13C
NMR: see Table 1; HRESIMS m/z 775.4577 (calculated for
C41H68O12Na, 775.4608).
2.6. Notoginsenoside-FZ (3)
20(S)-protopanaxadiol 3-O-b-D-xylopyranosyl-(1/2)-b-D-glu-
copyranosyl -(1/2)-b-D-glucopyranoside-20-O-a-L-arabinopyr-
anosyl-(1/6)-b-D-glucopyranoside (notoginsenoside-FZ): white
granulated crystal; [a]20 D¼12.2 (c¼ 0.44, MeOH); IR nmax 3426,
2924, 1650, 1458, 1384, 668 cm1; Libermann-Burchard and Molish
reactions were positive; 1H and 13C NMR: see Table 1; HRESIMSm/z
1233.6235 (calculated for C58H98O26Na, 1233.6244).
2.7. Acid hydrolysis of 1, 2, and 3
Solutions of compounds 1, 2, and 3 (5 mg each) in 2M HCl/MeOH
(4:1) (8 mL) were stirred at 90C for 2 hours. After cooling, each
Table 1
1H and 13C NMR (600 MHz, 150 MHz in C5D5N) data for 131)
Position 1 2 3
dC dH dC dH dC dH
1 39.3 0.95 m 39.5 0.96 m 39.1 0.73 m
1.49 m 1.62 m 1.51 m
2 26.6 1.81 m 28.1 1.32 m 26.7 1.34 m
2.22 m 1.84 m 1.80 m
3 88.6 3.36 dd
(12.0, 4.8)
77.8 3.40 dd
(10.8, 5.4)
88.7 3.28 dd
(11.4, 4.2)
4 39.6 39.4 39.6
5 56.2 0.68 m 56.2 0.78 m 56.2 0.66 m
6 18.3 1.36 m 18.6 1.42 m 18.3 1.35 m
1.44 m 1.52 m 1.48 m
7 35.1 1.17 m 35.1 1.21 m 35.0 1.19 m
1.37 m 1.41 m 1.45 m
8 39.7 39.7 39.9
9 50.5 1.46 m 50.5 1.52 m 50.1 1.35 m
10 37.0 37.4 36.8
11 29.9 1.32 m 30.0 1.38 m 30.6 1.54 m
1.90 m 1.98 m 1.96 m
12 79.6 3.66 m 79.6 3.63 m 70.6 4.15 m
13 49.7 1.58 m 49.7 1.60 m 49.4 1.97 m
14 51.2 51.2 51.3
15 32.4 1.13 m 32.4 1.13 m 30.7 0.97 m
1.47 m 1.49 m 1.54 m
16 25.5 2.08 m 25.4 2.12 m 26.5 1.80 m
2.34 m 2.33 m 2.18 m
17 46.4 3.19 ddd
(12.9, 8.
7, 4.6)
46.4 3.16 ddd
(12.9,
8.7, 4.4)
51.5 2.57 m
18 15.4 0.80 s 15.4 0.87 s 15.9 0.78 s
19 16.4 0.92 s 16.4 0.95 s 16.2 0.93 s
20 81.9 81.9 83.4
21 24.8 1.48 s 24.5 1.48 s 22.2 1.63 s
22 51.9 2.24 dd
(16.0, 9.6)
51.9 2.24 dd
(16.0, 9.6)
36.1 1.82 m
2.84 br d
(16.0)
2.85 br d (16.0) 2.39 m
23 72.6 4.82 br dd
(17.4, 7.8)
72.6 4.83 br dd
(17.4, 7.8)
23.1 2.38 m
2.57 m
24 129.1 5.52 d (7.8) 129.1 5.52 d (7.8) 125.8 5.31 m
25 131.2 131.1 131.0
26 25.6 1.82 s 25.6 1.81 s 25.7 1.61 s
27 18.9 1.65 s 18.8 1.65 s 17.8 1.64 s
28 28.0 1.29 s 28.5 1.20 s 28.0 1.26 s
29 16.7 0.99 s 16.2 1.02 s 16.6 1.09 s
30 16.9 1.15 s 16.9 1.10 s 17.3 0.94 s
3-O-sugar
Glc
G1 106.0 4.94 d (7.8) 104.7 4.93 d (7.8)
G2 75.7 4.03 m 82.9 4.10 m
G3 78.7 4.22 m 77.7 4.13 m
G4 72.2 4.03 m 71.7 4.23 m
G5 78.3 4.03 m 77.7 3.85 m
G6 63.0 4.62 dd
(12.0, 2.4)
62.9 4.35 m
4.41 dd
(11.4, 5.4)
4.57 br d
(12.0)
Glc0
G01 103.1 5.52 d (7.8)
G02 84.3 4.20 m
G03 78.2 3.95 m
G04 71.6 4.06 m
G05 77.9 4.29 m
G06 62.6 4.36 m
4.47 m
Xyl
X1 106.3 5.43 d (6.6)
X2 75.9 4.46 m
X3 79.2 4.18 m
X4 70.0 4.15 m
X5 67.3 3.68 m
4.30 m
20-O-sugars
Glc0 0
G0 01 99.2 5.11 d (7.8) 99.1 5.10 d (7.8) 98.0 5.14 d (7.8)
Table 1 (continued )
Position 1 2 3
dC dH dC dH dC dH
G0 02 75.2 3.95 dd
(7.9, 7.9)
75.1 3.95 dd
(7.9, 7.9)
74.8 3.93 m
G0 03 78.8 4.26 m 78.7 4.20 m 78.6 4.35 m
G0 04 71.8 4.22 m 72.1 4.21 m 71.0 3.96 m
G0 05 76.5 4.12 m 76.4 4.11 m 76.7 4.04 m
G0 06 69.0 4.80 m 68.9 4.80 m 69.1 4.25 m
4.10 m 4.10 m 4.70 m
Ara(f)
A1 110.3 5.69 d (1.8) 110.2 5.68 d
(1.8)
A2 83.4 4.95 m 83.3 4.94 m
A3 78.7 4.85 m 78.8 4.86 m
A4 85.8 4.75 m 85.8 4.76 m
A5 62.5 4.34 dd
(12.0, 2.4)
4.23 m
62.4 4.34 dd
(12.0, 2.4)
4.23 m
Ara(p)
A1 104.6 5.00 d (6.0)
A2 72.1 4.46 m
A3 74.1 4.22 m
A4 68.5 4.37 m
A5 65.6 3.79 m
4.30 m
HMBC, heteronuclear multiple bond correlation; HSQC, heteronuclear single quantum
correlation; NMR, nuclear magnetic resonance. m, multiplet; dd, double doublet; ddd,
double double doublet; s, singlet; br d, broad doublet; br dd, broad double doublet.
1) The assignments were based on HSQC and HMBC experiments.
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with CH2Cl2 (30mL 3). The aqueous layer was neutralizedwith 1M
KOH. After concentration, the residue was examined by thin layer
chromatography (TLC; n-BuOH/H2O/HOAc 3:2:1) and compared
with authentic samples [12]. The retention factor (Rf) values of
glucose, arabinose, and xylose were 0.38, 0.43, and 0.51, respectively.
2.8. Determination of sugar components
Monosaccharide subunits were obtained as described above.
The residue was dissolved in pyridine (0.5 mL) and then added to
trimethylchlorosilane (0.2 mL) and hexamethyldisilazane (0.5 mL).
The mixture was stirred at 20C for 15 minutes. The mixture was
then extracted with CH2Cl2 (2 mL) following the addition of H2O
(2 mL). The CH2Cl2 layer was examined by GC [12].
2.9. Inhibitory activity against PTP1B assay
The assay buffer (pH 7.4), consisting of 1 mM ethylene diamine
tetra acetic acid (EDTA), 50 mM 3,3-dimethyl glutarate, 5 mM
glutathione, and 0.5% fetal calf serum (FCS) (not heat inactivated)
was adjusted to an ionic strength of 0.15M by the addition of NaCl
[13]. Compounds (ﬁnal concentration ranging from 0 mM to 200 mM)
were added to the assay buffers containing PTP1B. The reaction
mixtures were allowed to stand at 37C for 5 minutes following the
addition of the compounds. The reactionwas started by the addition
of p-nitrophenyl phosphate and incubated for another 30 min, and
followed by the addition of 5 mL 0.5MNaOH solution to terminate the
reaction. The absorbance at 405 nmwas recorded using a microplate
absorbance reader to test the enzyme activity.
3. Results and discussion
3.1. Structure elucidation of compounds 13
Compound 1 was obtained as white amorphous powder. The
molecular formula of 1 was deduced to be C47H78O17 by positive
Fig. 1. The important HMBC and NOESY correlations of compounds 13. HMBC, het-
eronuclear multiple bond correlation; NOESY, nuclear Overhauser effect spectroscopy.
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(calculated for C47H78O17Na, 937.5137). The IR spectrum showed
absorption bands for hydroxyl (3425 cm1), oleﬁnic carbons
(1637 cm1), and ether moiety (1079 cm1). The 13C NMR (Table 1)
showed 47 carbon signals. The distortionless enhancement by po-
larization transfer (DEPT) spectrum exhibited eight methyls, 11
methylenes, 22 methines, and six quaternary carbons. Eight signals
of the aglycone moiety were assigned tomethyl carbons at [C-18 (dc
15.4), C-19 (dc 16.4), C-21 (dc 24.8), C-26 (dc 25.6), C-27 (dc 18.9), C-
28 (dc 28.0), C-29 (dc 16.7), C-30 (dc 16.9)]. Four oxygen substituted
carbons were observed at C-23 (dc 72.6), C-12 (dc 79.6), C-20 (dc
81.9), and C-3 (dc 88.6); a pair of oleﬁnic carbons were detected at
C-24 (dc 129.1) and C-25 (dc 131.2). This data, in combination with
the proton NMR signals, eight methyl groups at [d 0.80 (3H, s), 0.92
(3H, s), 0.99 (3H, s), 1.15 (3H, s), 1.29 (3H, s), 1.48 (3H, s), 1.65 (3H, s),
1.82 (3H, s)], three oxygen substituted protons at H-3 (dH 3.36 1H,
dd, J ¼ 12, 4.8 Hz), H-12 (dH 3.66, 1H, m), H-23 (dH 4.82, 1H, br dd,
J ¼ 17.4, 7.8 Hz), and one oleﬁn proton at H-24 (dH 5.52, 1H, d,
J¼ 7.8 Hz), suggested that 1 was a dammarane-type triterpene. The
1H and 13C signals were fully assigned according to heteronuclear
single quantum correlation (HSQC) spectra (Table 1). The NMR data
for the side-chain moiety of 1 were almost indistinguishable from
those of ginsenosides Rh18 [14]. Otherwise, its NMR spectra were
closely similar to those of notoginsenoside Fe [15], except the
presence of the ether linkage between C-12 and C-23. In the het-
eronuclear multiple bond correlation (HMBC) spectrum (Fig. 1), the
presence of long-range correlations between the proton signal at
H-23 (dH 4.82, 1H, br dd, J ¼ 17.4, 7.8 Hz) and carbon signals at C-12
(dc 79.6), C-24 (dc 129.1), and C-25 (dc 131.2) indicated the presence
of the ether linkage between C-12 and C-23. Moreover, key corre-
lation peaks were observed between the proton signal at H-1Glc (dH
4.94, 1H, d, J ¼ 7.8 Hz) and the carbon resonance signal at C-3 (dc88.6), H-1Glc0 0 (dH 5.11,1H, d, J¼ 7.8 Hz) and C-20 (dc 81.9), H-1Ara (dH
5.69, 1H, d, J ¼ 1.8 Hz), and C-6Glc0 0 (dc 69.0), which indicated that
the C-1Glc, C-1Glc0 0, and C-1Ara were linked to C-3, C-20 of the
aglycone, and C-6Glc0 0, respectively. Furthermore, the stereochem-
istry of 1 was conﬁrmed by the nuclear Overhauser effect spec-
troscopy (NOESY) spectrum (Fig. 1), and the correlation between
the proton signals at H-23 (dH 4.82,1H, br dd, J¼ 17.4, 7.8 Hz) and H-
12 (dH 3.66, 1H, m), H-12 (dH 3.66, 1H, m) and H-17 (dH 3.19, ddd,
J ¼ 12.9, 8.7, 4.6 Hz,), H-13 (dH 1.58, 1H, m) and H-21 (dH 1.48, 3H, s)
indicated the structure of 1 as in Fig. 2. The following abbreviations
are used: m¼multiplet, dd¼ double doublet, ddd¼ double double
doublet, s ¼ singlet, br d ¼ broad doublet, br dd ¼ broad double
doublet.
The sugar moieties of 1 were determined to be D-glucose (Glc)
and L-arabinose (Ara) [tR (min): 26.60 and 6.24] by GC. The stan-
dard monosaccharides were subjected to the same reaction and GC
analysis under the same condition. Retention times were consis-
tent. Three anomeric protons were observed at d 4.94 (1H, d,
J¼ 7.8 Hz), 5.11 (1H, d, J¼ 7.8 Hz), and 5.69 (1H, d, J¼ 1.8 Hz). On the
basis of HSQC, HMBC, NOESY correlations, and chemical reactions,
two b-D-glucopyranose (d 4.94 and 5.11) (Glc and Glc00) and one a-
L-arabinofuranosyl (d 5.69; Ara) were identiﬁed.
On the basis of the above analyses, compound 1 could be
deduced to be (20S,23R)-3b-hydroxy-12b,23-epoxy-dammar-24-
ene 3-O-b-D-glucopyranoside-20-O-a-L-arabinofuranosyl-(1/6)-
b-D-glucopyranoside (notoginsenoside-LX).
Compound 2 was obtained as white granulated crystal and
assigned the molecular formula C41H68O12, as determined from its
[MþNa]þ ion at m/z 775.4577 (calculated for C41H68O12Na,
775.4608) in the HRESIMS. Its IR spectrum also exhibited strong
absorption bands at 3419 cm1,1637 cm1, and 1043 cm1. TheNMR
data (Table 1) of 2wereclosely similar to thoseof 1. Comparedwith1,
the shift to upﬁeld of C-3 [11 parts per million (ppm)] and shift to
downﬁeld of C-2 (þ2 ppm) indicated that C-3 of 2 was linked to
hydroxyl. Comparison of the NMR data (Table 1) of 1 with those of 2
suggested that the only difference was the presence of one addi-
tional glucopyranosyl group in 1, and this was supported by the
presence ofmoreunits of 162 in themolecular formula of 1 than that
of 2. Besides, the NMR spectra of 2 were closely similar to those of
ginsenoside Mc [16], except the presence of the ether linkage be-
tween C-12 and C-23. All the proton and carbon signals for com-
pound 2 were assigned using 2D NMR spectra (Fig. 1). Therefore,
compound 2 could be established to be (20S,23R)-3b-hydroxy-
12b,23-epoxy-dammar-24-ene 20-O-a-L-arabinofuranosyl-(1/6)-
b-D-glucopyranoside (notoginsenoside-LY).
Compound 3 was obtained as white amorphous powder. It was
determined to have a molecular formula of C58H98O26 based on a
[MþNa]þ ion at m/z 1233.6235 (calculated for C58H98O26Na,
1233.6244) in the HRESIMS. The IR spectrum showed absorption
bands for hydroxyl (3426 cm1) and oleﬁnic carbons (1650 cm1).
The 1H NMR spectrum (Table 1) showed eightmethyl groups [d 0.78
(3H, s), 0.93 (3H, s), 1.63 (3H, s), 1.61 (3H, s), 1.64 (3H, s), 1.26 (3H, s),
1.09 (3H, s), 0.94 (3H, s)], one oleﬁnic proton [d 5.31 (1H, m)], two
oxygen substituted protons [d 3.28 (1H, dd, J ¼ 11.4, 4.2 Hz), 3.62
(1H, m)], and ﬁve anomeric protons [d 4.93 (1H, d, J ¼ 7.8 Hz), 5.52
(1H, d, J ¼ 7.8 Hz), 5.43 (1H, d, J ¼ 6.6 Hz), 5.14 (1H, d, J ¼ 7.8 Hz),
5.00 (1H, d, J ¼ 6.0 Hz)]. The 13C NMR (Table 1) showed 58 carbon
signals including a pair of oleﬁnic carbons at C-24 (dc 125.8) and C-
25 (dc 131.0). The chemical structure of 3 was further elucidated by
a HMBC (Fig. 1) experiment, in which the following correlations
were observed from H-3 (dH 3.28, 1H, dd, J ¼ 11.4, 4.2 Hz) to C-1Glc
(dc 104.7); H-1Glc0 (dH 5.52, 1H, d, J ¼ 7.8 Hz) to C-2Glc (dc 82.9); H-
1xyl (dH 5.43, 1H, d, J ¼ 6.6 Hz) to C-2Glc0 (dc 84.3); H-1Glc00 (dH 5.14,
1H, d, J ¼ 7.8 Hz) to C-20 (dc 83.4); and H-1Ara (dH 5.00, 1H, d,
J ¼ 6.0 Hz) to C-6Glc00 (dc 69.1). The NMR data for the tetracyclic part
Fig. 2. Structures of compounds 121. Ara(f), a-L-arabinofuranosyl; Ara(p), a-L-arabinopyranosyl; Glc, b-D-glucopyranosyl; Xyl, b-D-xylopyranosyl.
Table 2
Inhibitory effects of compounds 121 on PTP1B activity1)
Compound IC50 (mM) Compound IC50 (mM)
1 77.24 12 >100
2 29.08 13 >100
3 >100 14 >100
4 >100 15 21.27
5 >100 16 57.14
6 >100 17 >100
7 >100 18 >100
8 >100 19 >100
9 >100 20 28.12
10 >100 21 26.59
11 >100 Na3VO4 21.04
IC50, inhibitory concentration 50; PTP1B, protein tyrosine phosphatase 1B.
1) Na3VO4 was used as a positive control. The detailed methods for inhibitory
activity against PTP1B are described in Materials and methods. Values are means of
triplicate experiments.
J Ginseng Res 2014;38:28e3332of the aglycone and the glycosyl moieties linked to C-3 of aglycone
were similar to those of notoginsenoside Fa [15], and glycosyl
moieties linked to C-20 of aglycone were almost indistinguishable
from those of ginsenoside Rb2 [17].
The sugar moieties of 3 were determined to be D-glucose (Glc),
D-xylose (Xyl), and L-arabinose (Ara) [tR (min): 26.60, 8.86, and
6.23] by GC. The standard monosaccharides were subjected to the
same reaction and GC analysis under the same condition. Retention
times were consistent. Five anomeric protons were observed at
d 4.93 (1H, d, J ¼ 7.8 Hz), 5.52 (1H, d, J ¼ 7.8 Hz), 5.43 (1H, d,
J ¼ 6.6 Hz), 5.14 (1H, d, J ¼ 7.8 Hz), and 5.00 (1H, d, J ¼ 6.0 Hz). On
the basis of HSQC, HMBC, NOESY correlations and chemical re-
actions, three b-D-glucopyranose (d 4.93, 5.52, and 5.14) (Glc, Glc0,
and Glc00), one a-L-arabinopyranosyl (d 5.00) (Ara), and b-D-xylo-
pyranosy (d 5.43) (Xyl) were identiﬁed. The above evidence sug-
gested that 3 possesses the structure of 20(S)-protopanaxadiol 3-O-
b-D-xylopyranosyl-(1/2)-b-D-glucopyranosyl -(1/2)-b-D-glu-
copyranoside-20-O-a-L-arabinopyranosyl-(1/6)-b-D-glucopyr-
anoside (notoginsenoside-FZ).
3.2. Structure identiﬁcation of known compounds
The known compounds were identiﬁed as notoginsenoside-Fa
(4) [15], ginsenoside-Rb1 (5) [15], notoginsenoside-Fc (6) [15],
vina-ginsenoside-R7 (7) [18], ginsenoside-Rc (8) [17], ginseno-
side-Rd (9) [18], notoginsenoside-Fe (10) [15], gypenoside-IX (11)[15], 20(S)-ginsenoside-Rh1 (12) [19], 20(R)-ginsenoside-Rh1
(13) [19], ginsenoside-F1 (14) [20], 20(R)-protopanaxadiol (15)
[21], 20(S)-protopanaxadiol (16) [21], protopanaxatriol (17) [22],
panaxadiol (18) [21], 20(S)-ginsenoside-Rh2 (19) [23], 20(R)-
ginsenoside-Rh2 (20) [23], and 20(S)-ginsenoside-Mc (21) [16]
by NMR and mass spectrometric analyses and by comparison of
obtained values with literature values of the corresponding
compounds.
D. Li et al / Dammarane-type triterpenoids 333.3. PTP1B inhibitory activity
The current data (Table 2) suggest that protopanaxadiol
(PPD)-type aglycones are more effective than dammarane tri-
perpenoids having more than three sugars and that the presence
of sugar moieties reduces the PTP1B inhibitory activity of the
compounds. Compound 15 [20(R)-PPD] was more effective than
compound 16 [20(S)-PPD] with inhibitory concentration 50 (IC50)
values of 21.27 mM and 57.14 mM, respectively, despite the fact
that they differ from each other only by the absolute conﬁgura-
tion of chiral carbon of C-20. Compound 20 [20(R)-ginsenoside-
Rh2] was also more effective than compound 19 [20(S)-ginse-
noside-Rh2]. These results suggest that 20(R)-PPD-type tri-
terpenoids are more effective than 20(S)-PPD-type triterpenoids.
The IC50 values of 12, 13, 14, and 17 showed that protopanaxatriol
(PPT)-type triterpenoids exhibit no PTP1B inhibitory activity
at all.
Ginsenosides possess antidiabetic activity, but their mecha-
nisms are different. For example, ginsenoside Rb1 promotes adi-
pogenesis through the regulation of peroxisome proliferator-
activated receptor (PPAR)-g and microRNA-27b, providing a good
illustration to explain the antidiabetic effect of the ginsenoside [24].
The total saponins and ginsenoside Rb1 of ginseng stimulate the
secretion of glucagon-like peptide-1 (GLP1) in vivo and in vitro,
demonstrating an antidiabetic effect [25]. Ginsenoside Re reduces
insulin resistance by activating the PPAR-g pathway and inhibiting
tumor necrosis factor (TNF)-a production [26]. However, the cur-
rent study shows that the antidiabetic effects of P. notoginsengmay
be a result of the inhibitory activity of some ginsenosides against
PTP1B.
In the present study, we isolated three new dammarane-type
triterpenoids, elucidated as notoginsenoside-LX (1), notoginseno-
side-LY (2), and notoginsenoside-FZ (3), along with 18 known
compounds from P. notoginseng leaves and all compounds were
ﬁrstly evaluated for the inhibitory activity against PTP1B. Among
the three new dammarane-type triperpenoids, compound 2
showed similar strong activity comparable to the known com-
pounds 20 and 21. These results suggest that P. notoginseng leaves
can be used in folk medicine for their antidiabetic property and that
dammarane-type triterpenes enable this plant to be utilized for the
treatment of diabetes.Conﬂicts of interest
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